Resources

Dr Peter Feldschreiber co-authors article on the Regulatory Consequences of “Brexit” for the Development of Medicinal Products

News & Judgments
21 July 2017

Brexit is giving rise to great uncertainty regarding the future of life science research and development of new medicines in the UK.  This paper, published in this month’s Journal of Clinical Pharmacology and Therapeutics outlines the potential public health issues and commercial issues to all stakeholders in the Pharmaceutical industry by the disruption to the European life science products regulatory framework.  Dr Peter Feldschreiber and the team at 4 New Square will be happy to advise on these issues.

Related areas

Related People

Search

Tags

Expertise

Popular resources

Blurred boundaries: just how far do solicitors’ duties extend?


There has been a recent spate of cases where claimants have attempted…

Discover more

Stay of proceedings before serving a claim form


What should claimants do when limitation is about to expire? Noting…

Discover more

Four Fundamentals of Limitation Periods in Contract and Tort Claims


By Carl Troman, Barrister and Mediator at 4 New Square Four key points…

Discover more

If you would like to know more or have a question please talk to our clerks

Portfolio Builder

Select the expertise that you would like to download or add to the portfolio

Download    Add to portfolio   
Portfolio
Title Type CV Email

Remove All

Download


Click here to share this shortlist.
(It will expire after 30 days.)